Die folgenden Informationen liegen ausschließlich in englischer Sprache vor. 

LICIT Solutions GmbH, a spin-out from the Institute for Clinical Anatomy and Cell Analysis at the University of Tübingen, has successfully completed its Series A financing round. The round was led by ICIG Ventures, joined by Next Thursday GmbH, a syndicate of business angels, Startup BW Innovation Fonds GmbH & Co. KG, managed by Mittelständische Beteiligungsgesellschaft Baden-Württemberg (MBG), LBBW Venture Capital, and Chancenkapital Biberach. The financing was further supported by the InnoGrowth BW program of L-Bank.

The investors are enthusiastic about LICIT’s potential. Dr. Pelin Yilmaz, Investment Director at ICIG Ventures, commented: “We are pleased to reaffirm our commitment to LICIT Solutions as they advance towards broader market adoption. Their technology continues to demonstrate strong potential to redefine standards in the microbial control sector, combining efficacy with a compelling safety profile.” Dr. Josef Walek, Investmentmanager at MBG emphasized the market opportunity: “The growing demand for environmentally friendly and less harmful biocides is driven by stricter legal regulations and growing health and environmental awareness among consumers. We see considerable market potential for a new biocide with improved environmental and health profiles.” Dr. Wolfgang Klein, Managing Partner at Next Thursday GmbH added: “What convinced us is not only LICIT’s breakthrough innovation but also the highly committed founding team. We are confident they have the vision and execution strength to establish a new standard in the antimicrobial space.”